Michael Ehlers ('91)

At MPM, Dr. Ehlers helps direct the fund’s science-driven investment strategy by identifying and evaluating new breakthrough science around the world and turning it into business plans, management teams, and drug discovery and development programs. Ascidian Therapeutics is a clinical-stage RNA editing company developing exon editing technology for gene correction in hereditary diseases.